Alliqua Expands Patent Portfolio for Transdermal Drug Delivery Platform
Alliqua, Inc, an advanced biomedical products company focused on the development and manufacturing of proprietary drug delivery and liver health technologies, recently announced it has filed a provisional patent application with the US Patent and Trademark Office to enhance its transdermal delivery technology. The filing was based on positive test results with respect to specific chemical agents that improved the delivery of active ingredients when used in conjunction with the company’s hydrogel drug delivery platform. The patent application is directed to specific formulations that management believes will enhance the performance of its platform.
Â
“This patent filing is the second in a series of filings that we hope to continue as we develop additional improvements and processes,” said David Stefansky, Chairman of Alliqua, Inc. “These filings are a meaningful step in building our intellectual property portfolio, strengthening our drug delivery platform position, and in increasing shareholder value.”
Alliqua, Inc,Âis an advanced biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care, and liver health preservation.ÂThrough its wholly owned subsidiary, Alliqua BioMedical, Inc., Alliqua intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform of AquaMed Technologies, Inc., Alliqua’s subsidiary.
Â
AquaMed manufactures custom hydrogels used for transdermal drug delivery, wound care, medical diagnostics, and cosmetics. These products use proprietary manufacturing technologies that enable AquaMed to produce what is known in the healthcare industry as high water content, electron beam cross-linked aqueous polymer sheet hydrogels. AquaMed believes that it is one of two manufacturers in the world for these gels. Alliqua’s third subsidiary, HepaLife Biosystems, Inc., focuses on the development of a cell-based bioartificial liver system, known as HepaMate.
Total Page Views: 753
